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Single Cell Profiling of Potentiated
Phospho-Protein Networks in Cancer Cells
sion include mutations to key signaling proteins as well
as epigenetic changes to gene expression patterns (Ha-
nahan and Weinberg, 2000). Cancer genesis occurs in
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signals within cells. It might be predicted that genetic
changes common in cancers, such as receptor tyrosine
kinase mutations and other signaling-related cytoge-Summary
netic alterations (Spiekermann et al., 2002; Wheatley et
al., 1999), would change the potential of pre-existingAltered growth factor responses in phospho-protein-
signaling networks to respond to external stimuli anddriven signaling networks are crucial to cancer cell
lead to identifiable patterns of signal transduction asso-survival and pathology. Profiles of cancer cell signaling
ciated with gene mutation. For instance, acute myeloidnetworks might therefore identify mechanisms by which
leukemia (AML) is a cancer wherein dysregulated growthsuch cells interpret environmental cues for continued
and inhibition of apoptosis lead to the accumulation ofgrowth. Using multiparameter flow cytometry, we mon-
immature myeloid progenitor cells and oncogenic pro-itored phospho-protein responses to environmental
gression (Lowenberg et al., 1999). Two key parallel signalcues in acute myeloid leukemia at the single cell level.
transduction networks active in cells that are consideredBy exposing cancer cell signaling networks to potenti-
progenitors of AML (Reya et al., 2001) are the STATating inputs, rather than relying upon the basal levels
pathway (Coffer et al., 2000; Smithgall et al., 2000) andof protein phosphorylation alone, we could discern
the Ras/MAPK pathway (Platanias, 2003). Several re-
unique cancer network profiles that correlated with
ports suggest that STATs, such as Stat3 and Stat5, are
genetics and disease outcome. Strikingly, individual can- constitutively activated in AML (Benekli et al., 2002; Birk-
cers manifested multiple cell subsets with unique net- enkamp et al., 2001; Turkson and Jove, 2000; Xia et al.,
work profiles, reflecting cancer heterogeneity at the 1998). But, a causal link between basal STAT phosphory-
level of signaling response. The results revealed a dra- lation and leukemogenesis in primary patient material
matic remodeling of signaling networks in cancer has not been demonstrated, despite significant evi-
cells. Thus, single cell measurements of phospho-pro- dence implicating these proteins in oncogenic pro-
tein responses reveal shifts in signaling potential of a cesses (Benekli et al., 2003; Bowman et al., 2000; Buet-
phospho-protein network, allowing for categorizing of tner et al., 2002; Calo et al., 2003; Nieborowska-Skorska
cell network phenotypes by multidimensional molecu- et al., 1999). Thought to act upstream of these pathways,
lar profiles of signaling. abnormalities of the Flt3 (fms-like tyrosine kinase 3 )
receptor tyrosine kinase are detected in approximately
Introduction 30% of AML patients and are well established as a nega-
tive prognostic indicator in AML (Gilliland and Griffin,
Intracellular signaling and interpretation of environmen- 2002; Kottaridis et al., 2001; Thiede et al., 2002). Expres-
tal cues play central roles in cancer cell initiation and sion of mutant, activated Flt3 in cell lines has been ob-
maintenance. Actions that lead to cancer cell progres- served to activate STAT and Ras/MAPK signaling (Haya-
kawa et al., 2000; Mizuki et al., 2000). However, basal
levels of Stat5 phosphorylation have been reported to*Correspondence: gnolan@stanford.edu
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be statistically indistinguishable in Flt3 mutant and wild- as well as attenuated Stat1 phosphorylation following
type patient-derived AML blasts (Pallis et al., 2003). The cytokine stimulation. This is consistent with a model
differences observed between cell line studies and pri- where AML arises from proliferative signaling in the ab-
mary patient samples raises the question of why, in sence of differentiation and apoptosis. Therefore, po-
primary cells, there is not a strong linkage between acti- tentiated signaling can reveal relationships in phospho-
vating mutations in signaling proteins, increased basal protein networks that are reflective—either causal or
phosphorylation of putative targets, and disease state. reactive—of the mutations thought to initiate or sustain
Upon consideration, it could be proposed that it is the growth of a particular cancer phenotype and might
not the absolute level of the signaling proteins them- be applicable to mapping of signaling changes during
selves (or their basal phosphorylation status) that will normal development.
be most informative of cancer signaling processes, but
the manner in which such proteins perform in signaling
networks. A potentially informative approach to illumi- Results
nate the structure of signaling networks would be to
impose a signaling input on cancer cells and monitor Phospho-Protein Response Panel Distinguishes
changes in the level of phosphorylation on multiple key Leukemic Signal Transduction Networks
nodal proteins. As such, one could measure the effects A cytokine response panel, composed of 36 phospho-
of known (and unknown) mutations on signaling events protein states (6 basal states and 30 cytokine re-
in cancer cell subtypes. Furthermore, one could detect sponses), was designed to survey altered signal trans-
the influence of such mutations in sensitizing or potenti- duction of cancer cells (Figure 1A). Each square in the
ating the response of the cancer cell to other inputs grid approximates a multidimensional flow cytometry
or environmental cues. By providing multiple discrete file that contained at least 30,000 cell events. The cyto-
inputs to the signaling system, one is theoretically polar- kine responses of each phospho-protein node were
izing signaling networks to reveal their underlying struc- compared to the basal state (shown in this profile set
ture(s). Thus, by simultaneously measuring multiple as normalized to black) and represented by calculating
phosphorylation events at the single cell level across a the log2 fold difference in median fluorescence intensity
complex population of cancer cells, it would be possible (MFI) of stimulated sample divided by unstimulated sam-
to build and distinguish pathway anomalies in different ple. Although the data are visually simplified in a re-
cell subsets. This could allow for resolution, in different sponse panel, the multiparameter flow cytometry data
individuals, of those signaling profiles that differentiate are available for further inspection of single cell phos-
cancer subtypes and relate to disease progression. We pho-protein responses of interesting subsets, as exam-
describe this as interrogating the potentiation of signal- ined in detail later (Figure 5).
ing pathways—that is, stimulating a network to reveal The cytokine response panel included detection of
its signaling potential. phosphorylated Stat1, Stat3, Stat5, Stat6, p38, and
A cohort of adult AML patients with characterized Erk1/2. We collected data on unstimulated cells and
mutations in Flt3 and known cytogenetic abnormalities cells stimulated for 15 min with Flt3 ligand (FL), GM-
(Bruserud et al., 2003) provided us with an opportunity CSF, G-CSF, IL-3, or IFN. This panel was applied to
to compare gene mutations with signal transduction the U937 histiocytic lymphoma cell line (Figure 1A), the
profiles in primary cancer samples. To meet a standard HL-60 AML cell line, and multiple samples of a CD33
of measuring signaling events simultaneously in a con- subset from normal peripheral blood (Figure 1B). CD33
trolled context we used intracellular phospho-specific
cells represent differentiated cells of myeloid lineage
flow cytometry (Krutzik and Nolan, 2003; Perez and No-
and were used to assess variability in cytokine re-
lan, 2002) to detect multiple phosphorylated, activated
sponses among samples from blood donors. In general,signaling molecules in primary leukemic cells drawn
the cytokine responses of normal lymphocyte subsetsfrom this cohort of well-characterized AML patients.
differed very little between normal donors (2  0.1,Flow cytometry is useful in a clinical setting as relatively
n  6).small sample sizes—as few as 10,000 cells collected—
In contrast, the cytokine responses of AML cells var-can produce a considerable amount of statistically trac-
ied in numerous ways between patient samples. Thetable multidimensional signaling data and reveal key
cytokine response panels for 6/30 representative AMLcell subsets responsible for a phenotype (Krutzik et al.,
patient samples are shown (Figure 1C, AML-P012004). We tested the hypothesis that genetic alterations
through -P06). For example, although AML-P02 andto signaling genes would cause leukemic cells to react in
AML-P03 displayed many similarities, AML-P02 re-an inappropriate or sensitized manner to environmental
sponded to GM-CSF and G-CSF with phosphorylationinputs and that this differential signaling can be read
of Stat5 while AML-P03 responded only to GM-CSF atout by single cell flow cytometry.
Stat5 (Figure 1B). Additionally, although most patientHere, we apply potentiated signaling to interrogate
samples and controls displayed potent phosphorylationmultiple key nodal phospho-proteins in cancer net-
of Stat1 following IFN, AML-P05 lacked this response.works, map signaling mechanisms that unite cancer
Repeat measurements of cell lines, primary cell sam-subtypes, and demonstrate an intimate association be-
ples, and AML samples were collected (n  3) and thetween oncogene mutation, remodeling of signaling net-
technique and monoclonal antibodies displayed a highworks, and pathology. The profiles of signal transduc-
level of reproducibility similar to previous studies (Krut-tion that correlated with poor response to chemotherapy
showed potentiated Stat5 and Stat3 phosphorylations zik and Nolan, 2003).
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Figure 1. A Cytokine Response Panel Reveals Potentiated Signal Transduction Nodes in Primary Acute Myeloid Leukemias
(A) Stimulation states, shown in rows, included unstimulated or 20 ng/ml of FL, GM-CSF, G-CSF, IL-3, or IFN. Target phosphorylations were
detected using phospho-specific antibodies for Stat1, Stat3, Stat5, Stat6, p38, and Erk1/2, shown in columns. Each square in the grid represents
the response of one phosphorylation site to one condition. The relationship between the grid and the flow cytometry data on which it is based
is diagrammed for U937 cells.
(B) Representative cytokine response panels of the HL-60 AML cell line, normal CD33 leukocytes, and six AML patient samples. Repeat
experiments using these AML blasts yielded similar results (n  3), and variation among normal, healthy donors was minimal (n  6). The
response to stimulation at each signaling node is calculated as log2 (MFIstimulated/MFIunstimulated).
Basal Phosphorylation and Cytokine Responses phosphorylation states, we identified 7 of the 30 cyto-
kine response states that displayed significant varianceof STAT and Ras-MAPK Phospho-Proteins Vary
Significantly among Primary AML Patient Samples across AML patient samples (2 0.1, Figure 2B). These
were (1) phosphorylation of Stat3 following G-CSF, (2–5)Phospho-protein responses in many of the primary AML
blasts showed considerable induction and variance of phosphorylation of Stat5 following GM-CSF, G-CSF, IL-3,
and IFN, (6) Stat1 phosphorylation following IFN, andSTAT and RAS/MAP-K pathway member phosphoryla-
tion (Figure 2A). To illustrate the differences in the basal (7) phosphorylation of Erk1/2 following FL. The re-
maining cancer cytokine responses displayed variationstate across the AML samples, the first row of each
basal state has been represented according to a heat at or less than the variance in normal, differentiated
CD33 cells (Figure 1B). Including the two closest nodemap relative to the minimum among the 30 AML patient
blasts tested. As can be seen, there is considerable states to the significance threshold did not affect subse-
quent patient groupings (Supplemental Figure S1 atvariation across all basal nodes. However, some signal-
ing nodes remain activatable, and, following stimulation, http://www.cell.com/cgi/content/full/118/2/217/DC1).
Removing further nodes did affect the clustering, sug-we observed phosphorylation of associated signaling
proteins above the level observed in the basal state. In gesting that this collection of nodes represents the mini-
mum set of node states from this analysis for an accurateaddition to the considerable variation of the six basal
Cell
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Figure 2. Basal and Potentiated Signaling Nodes that Varied among Cancer Samples Were Used to Define an AML Biosignature
(A) The cytokine response panel of 30 total AML patient samples. The first row of each has been colored to show the variation in the basal
phosphorylation (relative to the minimum among the AML blasts). Of 900 cytokine responses assayed, 93 (10.3%) displayed a detectable
phosphorylation increase following stimulation (greater than 0.55-fold on a log2 scale).
(B) Significant cytokine responses were restricted primarily to the 7/30 cytokine response nodes with a variance across cancers greater than
0.1 (yellow circles).
(C) A graph of the absolute median plotted against the variance for each node state indicates the signal-to-noise threshold.
signaling profile. A graph of the absolute median against cal parameters—as opposed to pre-grouping patients
by clinical outcome and then testing each node statethe variance indicates the signal-to-noise threshold and
as a hypotheses—the statistical perils of multiple t teststhe relationship of variance to the median basal state
can be minimized or avoided (Tilstone, 2003). Thisor cytokine response (Figure 2C).
method also allows for disease subgroups to be identi-
fied even when normal control cells are rare or difficult
AML Patients with Similar Signal Transduction to obtain in bulk, as is the case with myeloid progenitor
Profiles Display Similar Chemotherapy cells (Reya et al., 2001), because differences among
Responses, Flt3 Mutations, experimental samples are used to define groups rather
and Cytogenetic Alterations than comparison of each sample to a proposed nor-
We composed a signal transduction based classification mal control.
for AML using unsupervised clustering of phospho-pro- Unsupervised clustering identified four main groups
tein biosignatures (Figure 3A). This was a first step in of AML patients (Figure 3A). Each of these groups was
determining whether underlying networks showed mecha- termed a signaling cluster (SC) and was referred to
nistic similarities to each other that corresponded with based on the primary signaling profile of the cluster: (1)
responsiveness to apoptotic induction by chemotherapy. SC-nonpotentiated (NP) had varied basal phosphoryla-
Samples were grouped using the complete linkage hierar- tion but displayed little or no potentiated phosphoryla-
chical clustering algorithm available in Multiple Experi- tion in response to cytokine induction and a low Stat1
ment Viewer (MeV) (http://www.tigr.org/software/tm4/ response to IFN (italic letters denote the cognate acro-
mev.html). There are several advantages to unsuper- nym), (2) SC-potentiated-basal (PB) displayed both a
vised clustering based on potentiated signaling. When potentiated phosphorylation response to cytokine and
patients are clustered according to a biological hypothe- high basal phospho-protein states, (3) SC-potentiated-1
(P1) displayed intense potentiated signaling, lower basalsis and then subsequently tested for correlation to clini-
Single Cell Potentiated Networks in Cancer
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Figure 3. AML Patients Grouped by Signal Transduction Biosignature Form Four Groups that Exhibit Significant Correlations to Clinical
Prognostic Markers
(A) The 13-parameter biosignatures of differentiated CD33 myeloid cells from six normal blood donors (D01 – D06), U937 and HL-60 cancer
cell lines, and 30 AML patient samples were grouped according to similarity using hierarchical clustering. The heat map for AML and cancer
cell line cytokine responses was scaled by subtracting donor sample medians to provide a dynamic color range. As shown previously, basal
responses are relative to the minimum among AML samples.
(B) Four main groups of AML patients were identified based on the similarity of their signal transduction biosignatures. We designated these
groups with signaling cluster (SC) nomenclature based on the signaling that defined them and mapped several clinical markers within the
identified patient groups.
phosphorylation, and a p-Stat1 response to IFN, and ations were grouped into a closely related branch (Figure
3, hierarchy branch AML-P23 through AML-P30) con-(4) SC-potentiated-2 (P2) displayed many potentiated
cytokine responses in the context of low basal phos- taining two patients with a 9;11 translocation (AML-P27
and AML-P24) and two patients with a loss of chromo-phorylation and a low Stat1 response to IFN.
Several clinical parameters were nonrandomly distrib- some 5 (AML-P23 and AML-P17). Patients with no de-
tected cytogenetic alterations formed a closely relateduted among the SCs, and four of these are aligned below
the heat map (Figure 3B). A full chart of known AML branch of SC-P2 (Figure 3A, hierarchy branch AML-P13
through AML-P20). This division of altered or diploidpatient characteristics, ordered by SC, is provided for
further analysis (Supplemental Table S1 on the Cell web- cytogenetics among branches of SC-NP and SC-P2 was
statistically significant (p  0.001).site). The 2 statistical test was used to determine the
significance of the observed correlations between clini- The signaling profiles and the activities represented
can be viewed in a more conventional network map (seecal factors previously determined to be prognostic for
AML and the biosignature-derived SCs. Figure 6) in an attempt to relate mechanism to signaling
outcome. With the SC-P2 cluster, a composite pathwayResistance to course one chemotherapy correlated
significantly with clustered signaling groups and oc- shows the action of multiple basal state activators (in
orange) that induce a “basal high” status for the targetedcurred primarily in patients with an SC-P2 profile (p 
0.002, Figure 3B). Patients with an SC-P2 profile consti- phospho-proteins (for SC-P2, only p-Stat5). In addition,
this map shows that one or more of several upstreamtuted 33% of this cohort (10/30) and were primarily de-
fined by potentiated Stat5 and Stat3 myeloid signaling activators can induce higher levels of phosphorylation
above the basal phosphorylation level (representing thatin the absence of Stat1 phosphorylation following IFN.
AML patient samples that displayed high myeloid cyto- these nodes are activatable). In contrast, with SC-NP pro-
files, high basal phosphorylation at signaling nodes waskine responses usually contained an internal tandem
duplication of Flt3—whereas the samples with a nonpo- observed (p-Erk1/2, p-Stat3, and p-Stat6), but additional
phosphorylation was not usually observed followingtentiated SC profile lacked these mutations (p  0.02).
In testing the correlation of six cell surface antigens with stimulation. These pathway maps are based on observa-
tions of signaling by flow cytometry (Figure 5) and areSC groups or Flt3, we noted that low expression of
CD15/Lewis X significantly correlated with SC-P2 and built to represent signaling clusters (Figure 3). Thus,
while individual AML samples showed differences fromFlt3 mutation (p  0.03 and p  0.001, respectively,
Figure 3B). the composite representations (Figure 7 and see Discus-
sion), signaling profile correlations can be clearly identi-In patients with an SC-NP profile, cytogenetic alter-
Cell
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Figure 4. Flt3 Mutation in Primary AMLs Is
Associated with Potentiated Myeloid Signal
Transduction Nodes
Basal and cytokine response node states of
patient samples with wild-type or mutant Flt3
are shown for the 30 AML samples assayed.
Each circle represents the level of STAT
phosphorylation detected in an individual
AML patient sample, grouped according to
wild-type Flt3 (black) or detected mutant Flt3
(yellow). (A) To assess basal phosphorylation,
samples were compared to the minimum ob-
served among cancers. (B–E) The phosphory-
lation of Stat5 detected following GM-CSF,
G-CSF, and IL-3 and of Stat3 following G-CSF
is shown as a fold increase above basal. (F)
Cumulative myeloid cytokine responses, cal-
culated by summing individual responses
(B–E), were compared in patients with and
without Flt3 mutations.
fied for groups (Figure 6), related to mechanisms, and Flt3 mutation (p  0.01, Figure 4E). Other cytokine re-
sponses were not observed to differ in patients with andused to form new hypotheses.
without Flt3 mutation. To represent a combined effect
of Flt3 mutation on myeloid signal transduction nodes,AML Blast Cells from Patients with Flt3 Mutations
Display Increased Stat5 and Stat3 we summed these four cytokine response node states.
This correlation between myeloid cytokine responsesPhosphorylation in Response
to GM-CSF and G-CSF and Flt3 mutation in AML patient samples was signifi-
cant (p  0.005), and all samples with detectable Flt3We used a t test to assess the significance of the ob-
served correlation between Flt3 mutation and poten- mutations displayed positive myeloid cytokine re-
sponses (Figure 4F). Thus, there is a strong linkage be-tiated myeloid signal transduction. The cytokine re-
sponses of patient samples with Flt3 mutations were tween the responsiveness of the cells to this set of
myeloid stimuli and oncogenic mutation of Flt3, sug-compared with patient samples that had no detectable
receptor tyrosine kinase mutation (Figure 4). We ob- gesting that activating mutations of Flt3 potentiate cer-
tain elements of the AML response beyond those whichserved no significant difference in the basal phosphory-
lation of Stat5 in either normal or Flt3 mutant AML sam- are canonically observed.
ples (Figure 4A), as had been previously observed in
patient samples (Pallis et al., 2003). Because expression Multidimensional Single Cell Profiling Reveals
Cancer Cell Subsets with Distinctof mutant Flt3 had been demonstrated to have a potent
effect on Stat5 phosphorylation in cell lines, we asked Signal Transduction Profiles
Flow cytometry has the ability to simultaneously mea-whether there was a connection between Flt3 mutations
and potentiated Stat5 and Stat3 phospho-protein sig- sure multiple events per cell and, as such, has allowed
the delineation of phenotypic distinctions of immunenaling.
Four of the p-Stat5 and p-Stat3 myeloid cytokine re- and other cell subsets. We aimed to determine whether
data simultaneously collected on two phospho-proteinsponses were identified as displaying significant vari-
ance across cancers (Figure 2; p-Stat3 following G-CSF, states (Krutzik et al., 2004) in these AML samples
showed signaling differences that suggested cancersand p-Stat5 following GM-CSF, G-CSF, and IL-3), so we
compared these responses in samples with and without were composed of different subsets of cells with distinct
signaling modes. Two-dimensional contour plots for theFlt3 mutation. Phosphorylation of Stat5 following GM-
CSF and G-CSF was significantly potentiated in patient G-CSF response of Stat5 and Stat3 are shown (Figure
5) grouped according to the signaling cluster hierarchysamples with Flt3 mutations (p 0.04 and 0.02, respec-
tively; Figures 4B and 4C). Sample calculations of t val- (which is correlated with the Flt3 mutational status)—for
cognate AML patient samples (see Supplemental Figureues are provided (Supplemental Table S2 online). Phos-
phorylation of Stat5 following IL-3 correlated with Flt3 S2 for a complete two-dimensional flow cytometry data-
set). G-CSF stimulated both Stat3 and Stat5 phosphory-status, but this was not statistically significant (p 0.07,
Figure 4D). Stat3 phosphorylation following G-CSF, the lation and, to a large extent, this dual signaling took
place simultaneously in individual cells. The linked po-only Stat3 biosignature response state displaying signif-
icant variance among AMLs, correlated significantly with tentiation of p-Stat5/G-CSF and p-Stat3/G-CSF in indi-
Single Cell Potentiated Networks in Cancer
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Figure 5. Representative 2D Flow Cytometry Plots of Stat5 and Stat3 Phosphorylation following G-CSF Stimulation in AML Patient Samples
with Wild-Type Flt3 and Mutant Flt3 (ITD)
Two-dimensional contour plot representations of Stat5 and Stat3 phosphorylation (y and x axis, respectively) in patient samples from SC-NP
and SC-P2. Both the level of basal phosphorylation and the response to G-CSF are shown.
vidual primary AML blast cells was most common in able mutations may indicate whether these mutations
successfully elicit potentiated signaling, which thesesamples with detectable Flt3 mutations (Figure 5B).
However, we noted the reproducible presence of single data suggest would be predictive of aggressive pathol-
ogy. Higher dimensional resolution with additional stim-positive subpopulations in some patients (note AML-
P13 and P20 as compared to P11). Thus, significant uli, or groups of stimuli, and downstream phospho-read-
outs could provide the additional data that wouldcancer heterogeneity at the level of signaling heteroge-
neity can be observed. provide a mechanistic insight to answer this question,
as discussed below.Four of the SC-NP profiles revealed the presence of
a small, induced, p-Stat5/p-Stat3 double-positive sub-
population (AML-P08, P23, P26, P30, Figure 5A). This Discussion
raises the interesting possibility that the presence of a
double positive, G-CSF-inducible p-Stat5/p-Stat3 sub- We observe that the varied genetic and clinical pheno-
types of leukemic cancers are profoundly linked to dis-population, independent of obvious Flt3 mutational sta-
tus, is predictive of an aggressive form of AML that is cernible patterns in phospho-protein signal transduction
networks. This allowed us to map signal transductionnot subject to DNA damage induction of apoptosis. In
some of these patients with a double positive p-Stat5/ mechanisms of cell subsets within individual patient
samples, cluster patient samples based on signalingp-Stat3 response to G-CSF, we did not observe Flt3
mutation, though it is possible that additional mutations profiles, and ultimately observe that certain leukemic
signaling profiles of phospho-protein targets were sig-in other regulators phenocopy the effect of the Flt3 mu-
tation. Of chemotherapy-treated patients with detect- nificantly linked with mutation of Flt3, cytogenetic
changes, expression of the cell surface marker CD15,able Flt3-ITD mutation and a non-SC-P2 profile (4
treated, 3 were too sick to be treated), 4/4 went into and response to chemotherapy. Critical to successful
clustering was the inclusion of the response of signalingremission following course 1 chemotherapy. In contrast,
7/7 patients with an SC-P2 profile and Flt3-ITD mutation networks to environmental cues, along with the basal
levels of phosphorylation. Such profiling can be usedrelapsed following chemotherapy. In this cohort, detec-
tion of an SC-P2-potentiated signaling profile provided to (1) understand signaling mechanisms in malignant
progression, (2) describe cancers by molecular pheno-a better prediction of chemotherapy response than that
obtained through identification of Flt3 mutation alone. type, and (3) translate this information for clinical appli-
cations. Thus, the signaling phenotype associated withTherefore, the signaling profile of samples with detect-
Cell
224
a particular cell context (differentiation state, activation signaling states (p-Stat5, p-Stat3, p-Erk1/2) found in
combination with a low p-Stat1/IFN response and highor proliferation capacity, mutation, or class of mutations)
basal Stat5 phosphorylation (Figure 3). This demon-can be revealed in the pattern of phosphorylations de-
strates that signal transduction-based classification oftected when that network is queried to process stimuli.
human cancer, a priori of knowledge of clinical outcome,
can produce a patient classification that is predictive ofPotentiated Signaling Reflects Underlying
response to therapy.Network Differences
Although a common SC-P2 profile emerged, at theFor many years, researchers have attempted to link ac-
individual sample level we observed differences intivities of protein(s) to phenotypic outcomes in cancer
signaling mechanisms contributing to STAT and Ras-progression and response to chemotherapy. We ob-
MAPK potentiation (Figures 7A–7C). For example, AML-served that by stimulating networks of phosphoproteins
P11, AML-P21, and AML-P29 were all profiled as SC-P2,in leukemic cells to respond to environmental cues, we
had detectable Flt3 mutations, and relapsed following“align” these proteins according to the network’s re-
chemotherapy. In looking at their individual signalingsponse potential. Thus, in AML cancers with varying
profiles, we see that AML-P11 had high basal Stat5pathology and disease origin, responses to environmen-
phosphorylation in resting cells but also was able total cues grouped AML types according to the underlying
phosphorylate Stat5 following G-CSF, IL-3, and IFN.performance boundaries of their signal transduction net-
Cells from AML-P21 displayed responses in p-Stat5 toworks (whose response is driven in part by the mutations
G-CSF and IFNbut lacked high resting phosphorylationthat occurred during the history of that cancer). As an
of Erk1/2 and Stat5. In AML-P29, we detected low basalexample, although AML-P14 and AML-P24 had rela-
phosphorylation but observed that Stat5 was phosphor-tively similar patterns of basal STAT and Ras-MAPK
ylated following numerous stimuli. While Stat5 providedpathway phosphorylation, these samples exhibited very
a common link in these signaling systems in that it wasdifferent phospho-protein patterns following cytokine
capable of being activated above basal levels, variationsstimulation (Figure 3A) and had differences in chemo-
existed in other nodes (see Figure 7 for details). Whattherapy response, Flt3 mutational status, and cytoge-
united this group was that cancers exhibiting a lack ofnetics (Figure 3B and Supplemental Table S1 online).
response to chemotherapy (a DNA damage-inducingSo while a profile of basal signaling alone would have
regimen that induces cell death via apoptosis) werefound these two patient samples to be similar, by using
composed of cell subsets with common potential tothe response to environmental cues combined with a
respond to one or more upstream cytokine activatorsclustering analysis to group similar molecular pheno-
and could frequently be detected to have an activatingtypes, we identified key differences in the signaling net-
mutation in a signaling gene (e.g., Flt3-ITD). In commonworks of the cancer cells in these two samples.
between SC-P2 and SC-NP was that both profiles por-Each response node in the cluster can be mapped to
tray at least one upregulated basal state that likely con-a potential for a phospho-protein to be activated by an
tributes to driving cellular division, but the ability to acti-upstream signaling event. Or, the node can be mapped
vate further signaling past basal levels was what enabled
as a basal state that is activated above background
correlation of signaling profiles with a lack of response
levels (shown in orange as an auxiliary input to the sig-
to chemotherapy.
naling system, Figures 6 and 7). Thus, we see there are
In the signaling cluster groups, basal phosphorylation
significant differences in signaling mechanisms defining differences helped distinguish between subgroups with
composite groupings of SC-P2 and SC-NP (Figure 6). cytogenetic alterations (branches of SC-NP and SC-P2,
The composite SC-P2 profile (which is characterized Figure 3). Patient samples with cytogenetic alterations
primarily by response to cytokine stimulation above were distinguished from samples with diploid cytoge-
basal levels) had high basal Stat5 and lower basal phos- netics in branches of the two main SCs (p  0.001,
phorylation at other nodes and could be potentiated for Figure 3). This suggests that the signal transduction
Stat5, Stat3, or Erk by one of many cytokines. In strong profile of leukemic blasts reflects the presence or ab-
contrast, SC-NP was nonresponsive to upstream stimuli sence of karyotypic abnormalities and that cytogenetic
but had varying basal high levels of Stat3, Stat6, and changes at different loci can lead to similar effects (phe-
Erk and was low basal for Stat5. Thus, the primary dis- nocopying) on the signal transduction profile of a cell.
tinction between the two groups was that one group In addition, correlation of Flt3 mutation with low CD15/
had low basal phosphorylation levels but responded to Lewis X antigen expression (p  0.001, Figure 3) had
environmental cues, while the second group had high not previously been reported. A connection between
internal basal phosphorylations at some of these phos- Flt3 signaling and CD15 expression has been observed
phoprotein nodes, but these nodes were nonresponsive in models of myeloid cell expansion where FL injection
to upstream environmental inputs such as cytokine stim- following transplantation of bone marrow cells to a
ulation. SCID-hu mouse resulted in increased relative numbers
Under this hypothesis of potentiated signaling, we of CD33/CD15	 cells (Namikawa et al., 1999).
predicted that particular signal transduction profiles, As reported by others (Pallis et al., 2003), we observed
such as niche-specific, pro-survival patterns, would cor- no significant difference in basal phosphorylation of
relate with resistance to chemotherapy-induced cell Stat5 between normal and Flt3 mutant AML patients
death. We observed that the response to course one (Figure 5). The results suggest that the presence of Flt3-
of chemotherapy was a relapse in 9/9 treated patients ITD is linked with potentiatiation or sensitization of the
whose samples displayed an SC-P2 profile (Figure 3), a phosphorylation of Stat5, and possibly Stat3, in re-
sponse to the myeloid cytokines GM-CSF and G-CSFpattern characterized by multiple potentiated myeloid
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Figure 6. Cancer Biosignatures and a Potentiated Model of Cancer Cell Signaling
(A) A general method for identifying a cancer biosignature is shown using an example of STAT and Ras/MAPK signaling node states in AML.
(B) Composite maps of cancer networks from profiles SC-NP and SC-P2 were built out of common signaling events observed in each cluster.
Highlighted nodes were detected to be high basal or potentiated in most of the samples from a profile group.
(Figures 4 and 5). The clustering of Flt3 mutational status be overcome using multiparameter approaches that dis-
tinguish cancer cell subset responses to input stimuli.with biosignature profiles supports the hypothesis that
gene mutations conferring proliferative advantages pro- For instance, although Stat3 and Stat5 are both thought
to be constitutively active in leukemias and share manyduce detectable signatures in the mitogenic signaling
network of cancer cells (Figures 6 and 7). structural similarities, in SC-P2, the Flt3-correlated po-
tentiation of the GM-CSF response only occurred with
Stat5 (data not shown, see Supplemental Figure S2);Cancer Heterogeneity at the Level
of Signaling Response Stat3 showed no response to GM-CSF in any of the
tested AML patient samples (Figures 2 and 5). In con-A critical advantage of single cell based biosignatures
is that, as shown above, they approximate complex data trast, in a given cell in SC-P2, the phosphorylation of
both Stat5 and Stat3 generally occurred simultaneouslywell enough to allow biologically significant clustering
while retaining the underlying flow cytometric data for following G-CSF stimulation (Figure 5). Interestingly,
multiple cancer subpopulations could be observed atfurther examination. We had also examined the original
2D plots of the phospho-protein expression profiles and the level of the signaling response. For example, AML-
P13 and AML-P20 each had a subpopulation of cellsobserved that higher dimensional representations of the
data identified subsets of cells with unique signaling fea- that were only p-Stat5 positive in response to G-CSF.
However, AML-P11 contained a subpopulation of cellstures.
Despite being composed of 95% leukemic blasts, that were p-Stat3 positive in the basal state but unre-
sponsive to the environmental cues applied in thesethe heterogeneity of cytokine responses among AML
samples—compared with cell lines or primary cell sub- experiments. Whether these subset differences repre-
sent simply nonresponsive cells, cancer “stem” cellssets (Figure 1)—shows the existence of multiple unique
cancer subsets based on signaling potential within indi- (Reya et al., 2001), or other stages of clonal evolution
within the cancer remains to be determined.vidual AML patients. Thus, the well-recognized limita-
tion for understanding cancer microheterogeneity might The linkage observed between dual responses and
Cell
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Figure 7. Three AML Patients Profiled as SC-P2 Showed Similarities and Differences in Potentiated Signaling Mechanisms
Pathway maps summarizing the signaling phenotype of individual patient samples are shown for three profiled as SC-P2, as per Figure 6.
Differences and similarities are highlighted in the text.
Flt3 status suggests strongly that Flt3 mutation can, in can be informative of cancer pathology. The finding that
potentiated cytokine responses of these cancers cansignificant subset(s) of cells as observed in two-dimen-
sional flow cytometry, lead to unexpected coactivation be combined with information on basal phosphorylation
states and clustered to create a classification with clini-of important phospho-protein transcription factors. Does
this represent a requirement during selective pressure cal relevance helps explain mechanism of signaling
functions and might inform the design of mechanism-that these cells maintain a low basal state of phosphory-
lation and then respond to appropriate stimuli for contin- based cancer therapies. In a broader context, the ap-
proach allows a distinction of cell types based on signal-ued cell division? Do the basal high states, combined
ing profiles in the absence of other specific knowledgewith nonresponsiveness to cytokine induction, of the
about the differentiation state or pathology of the cell. InSC-NP cancer cells represent a different “solution” that
this regard, we have observed examples of potentiatedallows for the maintenance of cell division of the cancer?
signaling in HIV-1 infection (J. Fortin and G.P.N., unpub-These two cancer escape strategies (distinguished by their
lished data) and in autoimmune systemic lupus erythe-network profiles) are differentially responsive to chemo-
matosus (P. Krutzik, M. Hale, and G.P.N., unpublishedtherapeutic induction—and might allow us to use this infor-
data). While other approaches for measuring multiplemation to design therapies to attack the aggressive cancer
events exist, they are usually carried out on “averaged”types based on the signaling profile that they present.
cell populations (gene chips or high throughput proteo-Extraction of additional high-dimensional information
mics), whereas multiparameter flow cytometry mea-could be applied to further refine our understanding of
sures the immediate response of signaling networks atsystems such as those presented here, especially when
the level of individual cells in complex populations. Mea-additional phospho-proteins or other single cell events
suring the resting state of signaling proteins, and howare measured simultaneously (Krutzik et al., 2004; Krut-
such proteins align in signaling networks to single orzik and Nolan, 2003). This could provide the additional
multiple inputs, in correlated datasets at the single cellinformation required to understand whether these sig-
level therefore provides a fuller understanding of hownaling systems are directly linked to apoptotic responses
cells process information in normal and diseased states.of proteins such as Bcl-2 and p53 (J.M.I., B.T.G., and
G.P.N., unpublished data).
Experimental Procedures
Summary Patients and Preparation of AML Blasts
This study of signaling mechanisms in primary cancer The study was approved by the local Ethics Committee and samples
collected after informed consent. Samples were selected from asamples indicates that an activated phospho-proteome
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large group of consecutive patients with de novo AML and high network. For an initial appraisal, the following rules were used. Basal
nodes were considered “basal high” when more than half the pa-peripheral blood blast counts (Bruserud et al., 2003). These patients
were admitted to the hospital from April 1999 to August 2003, the tients in a signaling cluster had signaling above the median for
cancers. Similarly, the responsiveness of a node state to an environ-median age was 60, and ages ranged from 29 to 84. As these patients
were selected for high blast counts, enriched AML cell populations mental cue was highlighted when more than half of the patient’s
node states in a profile group were above the median for cancers.containing95% cancer cells were prepared using a simple density
gradient separation of peripheral blood samples (Ficoll-Hypaque; Other node states were dimmed. Upon examination, the Stat1 re-
sponse to IFN was dimmed for both SC-NP and SC-P2, as thereNyCoMed, Oslo, Norway; specific density 1.077) before safe, stan-
dardized cryopreservation according to previously developed tech- was an attenuation of this signaling response, relative to donor PBL
controls, in both of the main signaling groups. The basal state ofniques (Bruserud et al., 2000). These patients represent the latter
portion of a group studied previously for Flt3 signaling and mutation p38 and Stat1 were high in SC-NP, but were not observed above
the median frequently enough to highlight their activity. Signalingin AML (Bruserud et al., 2003). The acute myeloid leukemia cell line
HL-60 and the monocytoid lymphoma cell line U-937 were from pathway maps were drawn based on multiple sources (McCubrey
et al., 2000; Rane and Reddy, 2002; Shuai and Liu, 2003; StirewaltAmerican Type Culture Collection (www.atcc.org) and cultured in
RPMI medium (Invitrogen, Carlsbad, California)  10% Fetal Calf and Radich, 2003).
Serum (HyClone, South Logan, Utah).
Acknowledgments
Stimulation of AML Blasts
Peripheral blood containing95% AML blasts was thawed into 5 ml We thank R. Tibshirani for insights on statistical approaches, O.
Vintermyr and A. Molven for making available c-kit and N-ras muta-Stem Span H3000 defined, serum-free medium (Stem Cell Technolo-
gies, Vancouver, BC, Canada), counted, pelleted, and resuspended tional analysis, A. Eliassen for assistance on Flt3 mutational analysis,
N. A˚nensen for many useful discussions, R. Smith, R. Wolkowicz,at 2 
 106 cells per ml. Six FACS tubes (Falcon 2052, BD-Biosci-
ences, San Jose, California) were then filled with 2 ml of each leuke- R. Ihrie, and P. Yam for review of this manuscript, and K. Vang for
administrative assistance. This work was supported by Nationalmia sample and allowed to rest at 37C for 2 hr. AML blasts were
resuspended gently to prevent aggregation and allowed to rest at Heart, Lung and Blood Proteomics Center Contract N01-HV-28183I.
O.D.P. is supported as a Bristol-Meyer Squibb Irvington-Institute37C for another 45 min. At this time, vehicle (deficient RPMI me-
dium, Invitrogen) or 40 l of stimulus was added to each tube to a Fellow and by the Dana Farber Foundation. We gratefully acknowl-
edge the support of BD Biosciences-Pharmingen, and the Baxterfinal concentration of 20 ng/ml. Stimuli included human recombinant
Flt3 ligand (FL), GM-CSF, G-CSF, IL-3, and IFN (all cytokines from Foundation. B.T.G. was supported by the Norwegian Research
Council Functional Genomics Program (FUGE) grant number 151859Peprotech, Inc., Rocky Hill, New Jersey). Samples were returned
to the 37C incubator for 15 min to allow signal transduction and and the Norwegian Cancer Society (DNK). R.H. and Ø.B. were sup-
ported by Helse Vest HF research grants. P.O.K. was supported byphosphorylation, after which 100 l of 32% para-formaldehyde
(PFA, Electron Microscopy Services Fort Washington, Pennsylvania) a Howard Hughes Medical Institute Predoctoral Fellowship. J.M.I.
was supported by the James H. Clark Stanford Graduate Fellowshipwas added to each 2 ml tube of cells to a final concentration of
1.6%. Cells were fixed for 15 min at room temperature, pelleted, and the J.G. Lieberman Fellowship.
then permeabilized by resuspension in 2 ml ice cold methanol for
10 min, and stored at 4C until being stained for flow cytometry. Received: January 10, 2004
Revised: May 28, 2004
Accepted: May 28, 2004Intracellular Phospho-Specific Flow Cytometry
PFA fixed, methanol permeabilized AML blasts were rehydrated by Published: July 22, 2004
adding 2 ml phosphate-buffered saline (PBS), gentle resuspension,
and then centrifugation. The cell pellet was washed once with 2 ml References
PBS, resuspended in 150 l PBS  0.1% BSA (Sigma, St. Louis,
Missouri), and split evenly into three new FACS tubes. Fifty microli- Benekli, M., Xia, Z., Donohue, K.A., Ford, L.A., Pixley, L.A., Baer,
ters of an antibody mix containing 0.065 g primary conjugated M.R., Baumann, H., and Wetzler, M. (2002). Constitutive activity of
phospho-specific antibody per sample was added to each tube of signal transducer and activator of transcription 3 protein in acute
AML blasts and staining proceeded for 20 min at room temperature. myeloid leukemia blasts is associated with short disease-free sur-
Alexa (Ax) dye (Molecular Probes, Eugene, Oregon) conjugated anti- vival. Blood 99, 252–257.
bodies (all from BD-Pharmingen, San Diego, California) included
Benekli, M., Baer, M.R., Baumann, H., and Wetzler, M. (2003). Signal
antibodies against phospho-Stat3(Y705)-Ax488, phospho-Stat5
transducer and activator of transcription proteins in leukemias.
(Y694)-Ax647, phospho-Stat6(Y641)-Ax488, phospho-Stat1(Y701)-
Blood 101, 2940–2954.
Ax647, phospho-p38(T180/Y182)-Ax488, and phospho-Erk1/2(T202/
Birkenkamp, K.U., Geugien, M., Lemmink, H.H., Kruijer, W., andY204)-Ax647 and were applied in pairs (Stat5/Stat3, Stat1/Stat6,
Vellenga, E. (2001). Regulation of constitutive STAT5 phosphoryla-and Erk/p38) for subsequent detection of Ax488 and Ax647 on FL-1
tion in acute myeloid leukemia blasts. Leukemia 15, 1923–1931.and FL-4, respectively. Approximately 30,000 ungated events were
collected for each sample on a benchtop FACSCalibur dual-laser Bowman, T., Garcia, R., Turkson, J., and Jove, R. (2000). STATs in
cytometer (Becton Dickinson, Franklin Lakes, New Jersey). oncogenesis. Oncogene 19, 2474–2488.
Bruserud, O., Gjertsen, B.T., and von Volkman, H.L. (2000). In vitro
Statistical Analysis culture of human acute myelogenous leukemia (AML) cells in serum-
Changes in phosphorylation of STAT and Ras-MAPK proteins fol- free media: studies of native AML blasts and AML cell lines. J.
lowing cytokine stimulation were approximated by calculating the Hematother. Stem Cell Res. 9, 923–932.
log2 ratio of median fluorescence intensity (MFI) of stimulated versus Bruserud, O., Hovland, R., Wergeland, L., Huang, T.S., and Gjertsen,
unstimulated cell populations. Differences in basal phosphorylation B.T. (2003). Flt3-mediated signaling in human acute myelogenous
were compared by calculating the log2 ratio of each sample’s MFI leukemia (AML) blasts: a functional characterization of Flt3-ligand
divided by the minimum among cancers. To determine the statistical effects in AML cell populations with and without genetic Flt3 abnor-
significance of observed versus expected distributions, we used a malities. Haematologica 88, 416–428.
2 test (Figure 3B), and to determine the significance of the difference
Buettner, R., Mora, L.B., and Jove, R. (2002). Activated STAT signal-in mean of two populations, we used a student’s t test (  0.05,
ing in human tumors provides novel molecular targets for therapeu-Figure 4). Standard t tests were used to validate existing hypotheses
tic intervention. Clin. Cancer Res. 8, 945–954.(Kiyoi et al., 2002; Mizuki et al., 2003).
Calo, V., Migliavacca, M., Bazan, V., Macaluso, M., Buscemi, M.,
Gebbia, N., and Russo, A. (2003). STAT proteins: from normal controlDerivation of Signaling Pathway Maps
of cellular events to tumorigenesis. J. Cell. Physiol. 197, 157–168.Pathways considered important to the signaling profiles of SC-NP
and SC-P2 were identified and highlighted in a model of the probed Coffer, P.J., Koenderman, L., and de Groot, R.P. (2000). The role of
Cell
228
STATs in myeloid differentiation and leukemia. Oncogene 19, 2511– Smithgall, T.E., Briggs, S.D., Schreiner, S., Lerner, E.C., Cheng, H.,
and Wilson, M.B. (2000). Control of myeloid differentiation and sur-2522.
vival by Stats. Oncogene 19, 2612–2618.Gilliland, D.G., and Griffin, J.D. (2002). The roles of FLT3 in hemato-
Spiekermann, K., Pau, M., Schwab, R., Schmieja, K., Franzrahe, S.,poiesis and leukemia. Blood 100, 1532–1542.
and Hiddemann, W. (2002). Constitutive activation of STAT3 andHanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer.
STAT5 is induced by leukemic fusion proteins with protein tyrosineCell 100, 57–70.
kinase activity and is sufficient for transformation of hematopoietic
Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T.,
precursor cells. Exp. Hematol. 30, 262–271.
Saito, H., and Naoe, T. (2000). Tandem-duplicated Flt3 constitutively
Stirewalt, D.L., and Radich, J.P. (2003). The role of FLT3 in haemato-activates STAT5 and MAP kinase and introduces autonomous cell
poietic malignancies. Nat. Rev. Cancer 3, 650–665.growth in IL-3-dependent cell lines. Oncogene 19, 624–631.
Thiede, C., Steudel, C., Mohr, B., Schaich, M., Schakel, U., Platz-Kiyoi, H., Ohno, R., Ueda, R., Saito, H., and Naoe, T. (2002). Mecha-
becker, U., Wermke, M., Bornhauser, M., Ritter, M., Neubauer, A.,nism of constitutive activation of FLT3 with internal tandem duplica-
et al. (2002). Analysis of FLT3-activating mutations in 979 patientstion in the juxtamembrane domain. Oncogene 21, 2555–2563.
with acute myelogenous leukemia: association with FAB subtypes
Kottaridis, P.D., Gale, R.E., Frew, M.E., Harrison, G., Langabeer, and identification of subgroups with poor prognosis. Blood 99,
S.E., Belton, A.A., Walker, H., Wheatley, K., Bowen, D.T., Burnett, 4326–4335.
A.K., et al. (2001). The presence of a FLT3 internal tandem duplica-
Tilstone, C. (2003). DNA microarrays: vital statistics. Nature 424,tion in patients with acute myeloid leukemia (AML) adds important
610–612.prognostic information to cytogenetic risk group and response to
Turkson, J., and Jove, R. (2000). STAT proteins: novel molecularthe first cycle of chemotherapy: analysis of 854 patients from the
targets for cancer drug discovery. Oncogene 19, 6613–6626.United Kingdom Medical Research Council AML 10 and 12 trials.
Blood 98, 1752–1759. Wheatley, K., Burnett, A.K., Goldstone, A.H., Gray, R.G., Hann, I.M.,
Harrison, C.J., Rees, J.K., Stevens, R.F., and Walker, H. (1999). AKrutzik, P.O., and Nolan, G.P. (2003). Intracellular phospho-protein
simple, robust, validated and highly predictive index for the determi-staining techniques for flow cytometry: Monitoring single cell signal-
nation of risk-directed therapy in acute myeloid leukaemia deriveding events. Cytometry 55A, 61–70.
from the MRC AML 10 trial. United Kingdom Medical ResearchKrutzik, P.O., Irish, J.M., Nolan, G.P., and Perez, O.D. (2004). Analysis
Council’s Adult and Childhood Leukaemia Working Parties. Br. J.of protein phosphorylation and cellular signaling events by flow
Haematol. 107, 69–79.cytometry: techniques and clinical applications. Clin. Immunol.
Xia, Z., Baer, M.R., Block, A.W., Baumann, H., and Wetzler, M. (1998).110, 206–221.
Expression of signal transducers and activators of transcription pro-Lowenberg, B., Downing, J.R., and Burnett, A. (1999). Acute myeloid
teins in acute myeloid leukemia blasts. Cancer Res. 58, 3173–3180.leukemia. N. Engl. J. Med. 341, 1051–1062.
McCubrey, J.A., May, W.S., Duronio, V., and Mufson, A. (2000). Ser-
ine/threonine phosphorylation in cytokine signal transduction. Leu-
kemia 14, 9–21.
Mizuki, M., Fenski, R., Halfter, H., Matsumura, I., Schmidt, R., Muller,
C., Gruning, W., Kratz-Albers, K., Serve, S., Steur, C., et al. (2000).
Flt3 mutations from patients with acute myeloid leukemia induce
transformation of 32D cells mediated by the Ras and STAT5 path-
ways. Blood 96, 3907–3914.
Mizuki, M., Schwable, J., Steur, C., Choudhary, C., Agrawal, S.,
Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Bohmer, F.D.,
et al. (2003). Suppression of myeloid transcription factors and induc-
tion of STAT response genes by AML-specific Flt3 mutations. Blood
101, 3164–3173.
Namikawa, R., Muench, M.O., Firpo, M.T., Humeau, L., Xu, Y.,
Menon, S., and Roncarolo, M.G. (1999). Administration of Flk2/Flt3
ligand induces expansion of human high-proliferative potential col-
ony-forming cells in the SCID-hu mouse. Exp. Hematol. 27, 1029–
1037.
Nieborowska-Skorska, M., Wasik, M.A., Slupianek, A., Salomoni, P.,
Kitamura, T., Calabretta, B., and Skorski, T. (1999). Signal transducer
and activator of transcription (STAT)5 activation by BCR/ABL is
dependent on intact Src homology (SH)3 and SH2 domains of BCR/
ABL and is required for leukemogenesis. J. Exp. Med. 189, 1229–
1242.
Pallis, M., Seedhouse, C., Grundy, M., and Russell, N. (2003). Flow
cytometric measurement of phosphorylated STAT5 in AML: lack of
specific association with FLT3 internal tandem duplications. Leuk.
Res. 27, 803–805.
Perez, O.D., and Nolan, G.P. (2002). Simultaneous measurement of
multiple active kinase states using polychromatic flow cytometry.
Nat. Biotechnol. 20, 155–162.
Platanias, L.C. (2003). Map kinase signaling pathways and hemato-
logic malignancies. Blood 101, 4667–4679.
Rane, S.G., and Reddy, E.P. (2002). JAKs, STATs and Src kinases
in hematopoiesis. Oncogene 21, 3334–3358.
Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001).
Stem cells, cancer, and cancer stem cells. Nature 414, 105–111.
Shuai, K., and Liu, B. (2003). Regulation of JAK-STAT signalling in
the immune system. Nat. Rev. Immunol. 3, 900–911.
